2014—2018年我国七城市二肽基肽酶Ⅳ抑制剂和胰高血糖素样肽1受体激动剂及钠-葡萄糖共转运蛋白2抑制剂使用情况调查  

Analysis of dipeptidyl peptidase Ⅳ inhibitor,glucagon-like peptide 1 receptor agonist and sodium-glucose co-transporter 2 inhibitor in 7 cities in China from 2014 to 2018

作　　者：周洋[1] 石秀锦[1] 彭文星[1] 林阳[1] 魏娟娟[1] 方振威[1] Zhou Yang;Shi Xiujin;Peng Wenxing;Lin Yang;Wei Juanjuan;Fang Zhenwei(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院药事部

出　　处：《中国医药》2020年第1期130-134,共5页China Medicine

基　　金：国家重点研发计划(2017YFC0908800)~~

摘　　要：目的通过调查我国7个城市二肽基肽酶Ⅳ抑制剂(DPP-4i)和胰高血糖素样肽1受体激动剂(GLP-1RA)及钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)的使用情况及用药趋势,为促进药物合理使用提供基础参考数据。方法数据来源于2014年1月至2018年12月中国药学会医院药学专业委员会"医院处方分析合作项目"收集的我国7个城市中87家各级样本医疗卫生机构的抽样处方,对患者用药情况进行分析。结果5年来,7个城市DPP-4i,GLP-1RA,SGLT2i这3类降糖药物的销售金额呈逐年上升趋势,2018年药品销售金额中,DPP-4i(1643.81万元)>GLP-1RA(394.56万元)>SGLT2i(48.23万元)。药品销售金额排名前5位分别为西格列汀(828.63万元)、沙格列汀(393.12万元)、利拉鲁肽(375.97万元)、维格列汀(188.15万元)、利格列汀(131.15万元)。结论2014-2018年我国7城市DPP-4i、GLP-1RA和SGLT2i这3类新型降糖药物的使用较为合理,临床治疗中医师优先选择疗效和经济性较好的品种。Objective To investigate the usage of dipeptidyl peptidase Ⅳ inhibitor(DPP-4i),glucagon-like peptide 1 receptor agonist(GLP-1RA) and sodium-glucose co-transporter 2 inhibitor(SGLT2i) in 7 cities in China,in order to provide reference data for promoting the rational use of hypoglycemic drugs.Methods Prescription data were collected from 87 medical and health institutions in 7 cities under the management of "the Hospital Prescriptions Cooperation Project" of Hospital Pharmacy Committee of Chinese Pharmaceutical Association from January 2014 to December 2018.Use of DPP-4i,GLP-1RA and SGLT2i was analyzed.Results During the 5 years,the sales amounts of DPP-4i,GLP-1RA and SGLT2i in the 7 cities were increasing.In 2018,the sales amount was 16438.1 thousand yuan of DPP-4i,3945.6 thousand yuan of GLP-1RA and 482.3 thousand yuan of SGLT2i.The top 5 drugs were sitagliptin(8286.3 thousand yuan),saxagliptin(3931.2 thousand yuan),liraglutide(3759.7 thousand yuan),vildagliptin(1881.5 thousand yuan) and linagliptin(1311.5 thousand yuan).Conclusions The use of three new types of hypoglycemic drugs including DPP-4i,GLP-1RA and SGLT2i was rational in 7 cities in China from 2014 to 2018.In clinical practice,physicians prefer the medication choice with high cost-effectiveness.

关 键 词：二肽基肽酶Ⅳ抑制剂 胰高血糖素样肽1受体激动剂 钠-葡萄糖共转运蛋白2抑制剂 降糖药 使用现状 

分 类 号：R977[医药卫生—药品]